Cabozantinib for unresectable soft tissue mets

[Olga]

In case when there are soft tissue mets that could not be resected without significant morbidity/quality of life loss, it seems that Cabozantinib might be a rare option to try to reduce the met allowing its consecutive resection/ablation/radiosurgery.
There is an important information from the trial of this drug in prostate cancer
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
http://www.ncbi.nlm.nih.gov/pubmed/23169517
They found that "Seventy-two percent of patients had regression in soft tissue lesions, whereas 68% of evaluable patients had improvement on bone scan, including complete resolution in 12%." It is hard to say if this result is going to be the same in ASPS but it is a reasonable option to try since ASPS is a MET expressing tumor.